ARID1A and female reproductive organ cancer: The role of specific HDAC inhibitors, such as ACY1215, an HDAC6 inhibitor, further illustrates epidrugs’ therapeutic potential in ICI therapy for gynecological cancers with ARID1A mutations [197].